Novocure Shares Rise After Co Boosts FY26 Revenue Guidance

Dow Jones

07/23

Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter.

The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year.

Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier.

Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million.

Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability.

Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 23, 2026 10:03 ET (14:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2653725705"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653725705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653725705?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653725705","market":"sh","top_or_hot":-1,"title":"Novocure Shares Rise After Co Boosts FY26 Revenue Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n</p>\n<p>\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n</p>\n<p>\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n</p>\n<p>\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n</p>\n<p>\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 10:03 ET (14:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Shares Rise After Co Boosts FY26 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Shares Rise After Co Boosts FY26 Revenue Guidance\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-23 22:03</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n</p>\n<p>\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n</p>\n<p>\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n</p>\n<p>\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n</p>\n<p>\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 10:03 ET (14:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653725705","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653725705","pubTimestamp":1784815380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter.The stock was up 26% to $19.59 in recent tr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","NVCR":"NovoCure Limited","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4082":"医疗保健设备"},"translate_title":"公司上调 26 财年收入指引后，Novocure 股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n\n\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n\n\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n\n\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n\n\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n\n\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2026 10:03 ET (14:03 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}